Definium Therapeutics, Inc. (DFTX) Stock: Price, Forecast & Analyst Target
Definium Therapeutics, Inc. (DFTX) — MoonshotScore 57/100 (Fair band), calculated Nov 18, 2026. Price $29.48 (+1.24%), as of the Nov 19, 2026 trading session; market cap $4.04B. Expected results Feb 25, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Definium Therapeutics, Inc. · DFTX · NASDAQ · Healthcare · Biotechnology
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Definium Therapeutics (DFTX)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet, but stalling growth and a full valuation; the market is already moving on it. Business Quality: Average; Financial Safety: Sound; Valuation: Full; Growth Durability: Shrinking; Momentum: Surging.
- EPS beat 2 of the last 8 reports
- Altman Z 21.68 · Piotroski F 3
- ROE -54.0% · ROA -31.4% · current ratio 15.53 · earnings yield -7.9% · free-cash-flow yield -4.4%
Holding back: soft growth
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 60 | Fair | |
| 61 | Fair | |
| 59 | Fair | |
| 59 | Fair | |
| 57 | Fair | |
| 57 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $29.48 | |
| Change on the day | +1.24% | |
| 52-week range | $10.46–$49.70 | |
| Market capitalisation | $4.04B | — |
| Shares traded on the day | 3.07M | |
| Beta (volatility vs the S&P 500) | 2.21 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Definium Therapeutics (DFTX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Definium Therapeutics (DFTX), and what does it report?
Short answer
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Definium Therapeutics, Inc. (DFTX) is listed on NASDAQ. Definium Therapeutics, Inc. (DFTX) is classified as Healthcare / Biotechnology. SEC filing business address: ONE World Trade Center, Suite 8500, NEW York, NY, 10007. It employs 106 people and is led by Robert Barrow. The market values it at $4.04B.
What do the latest results show for Definium Therapeutics (DFTX)?
Short answer · as of
Against analyst estimates the company has EPS beat 2 of the last 8 reports.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · EPS vs estimate
- Above estimate Nov 9, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 9, 2026 | Not available | Not available | −$0.4600 | −$0.5629 |
| Aug 6, 2026 | Not available | Not available | −$1.4400 | −$0.5410 |
| May 7, 2026 | Not available | Not available | −$0.7100 | −$0.4700 |
| Feb 26, 2026 | Not available | Not available | −$0.5100 | −$0.4837 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
What are the financial strengths and risks for Definium Therapeutics (DFTX)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway. The MoonshotScore pillars rate balance-sheet strength, positive momentum as strengths. What is holding it back is soft growth. The distress and quality screens read Altman Z 21.68 · Piotroski F 3. Trailing ratios: ROE -54.0% · ROA -31.4% · current ratio 15.53 · earnings yield -7.9% · free-cash-flow yield -4.4%.
Data-derived red flags
- Negative return on equity (-54.0%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Definium Therapeutics (DFTX)?
Short answer · as of
The next earnings report is expected on Feb 25, 2027. The number it tests is the $-2.97 EPS analysts carry for it. Analyst estimates on file carry FY2026 revenue $0.00 · EPS -2.97 · 0 analysts. Current published price targets run low $52.00 · high $79.00 · consensus $67.45 · median $68.00 against a quoted price of $29.48 (as of Nov 19, 2026).
What the records here don't tell us
- No quarterly income statement is held for DFTX.
Checked against the records this page reads, on the dates shown above.
How does Definium Therapeutics compare with its peers?
Short answer
Definium Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.56 Nov 18, 2026 | $3.01B | 97 5-pillar Nov 18, 2026 | |
| $58.26 Nov 19, 2026 | $2.97B | 95 5-pillar Nov 18, 2026 | |
| $27.61 Nov 18, 2026 | $3.49B | 89 5-pillar Nov 18, 2026 | |
| $41.17 Nov 19, 2026 | $4.51B | 84 5-pillar Nov 18, 2026 | |
| $19.50 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $47.40 Nov 19, 2026 | $1.41B | 76 5-pillar Nov 18, 2026 | |
| $46.41 Nov 19, 2026 | $3.42B | 72 5-pillar Nov 18, 2026 | |
| $298.71 Nov 18, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $17.83 Nov 18, 2026 | $3.08B | 68 5-pillar Nov 18, 2026 | |
| $14.22 Nov 19, 2026 | $4.99B | 67 5-pillar Nov 18, 2026 | |
| $26.20 Nov 19, 2026 | $3.37B | 66 5-pillar Nov 18, 2026 | |
| $124.39 Nov 19, 2026 | $5.25B | 66 5-pillar Nov 18, 2026 | |
| Definium Therapeutics (DFTX) — this page | $29.48 | $4.04B | 57 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $52.00 – $79.00
- Consensus target
- $67.45
- Median target
- $68.00
- Revenue estimate
- $0.00
- EPS estimate
- $-2.97
Consensus record · Captured .
Measured against a quoted price of $29.48 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 25, 2026
- Transactions
- 43
- Identified insiders
- 11
- Purchases
- 0
- Sales
- 11
- Other transactions
- 32
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held DFTX in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 0% | $0 | Sold out (was $16.77M) |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Definium Therapeutics (DFTX)?
- Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT at 2026 NEI Fall Congress
- Definium Therapeutics To Present Phase 3 Panorama Data Of LSD-Based DT120 In Generalized Anxiety Disorder, Pooled Phase 3 Safety At NEI Congress
- Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
- Definium Therapeutics Announces Participation in Upcoming Investor Conferences
DFTX Healthcare Stock FAQ
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for DFTX?
DFTX carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is DFTX a good stock to buy?
Stock Expert AI does not rate DFTX buy, sell or hold. Definium Therapeutics, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the DFTX stock price today?
The last price recorded for Definium Therapeutics, Inc. (DFTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the DFTX price target?
The analyst consensus price target for Definium Therapeutics, Inc. (DFTX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key factors to evaluate for DFTX?
Definium Therapeutics, Inc. (DFTX) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. No dividend yield reflects the company's focus on reinvesting earnings into research and development. Not financial advice.
How frequently does DFTX data refresh on this page?
DFTX's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven DFTX's recent stock price performance?
Definium Therapeutics, Inc. (DFTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel product candidates targeting unmet needs in brain health. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DFTX overvalued or undervalued right now?
Definium Therapeutics, Inc. (DFTX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of DFTX?
Fractional-share availability for Definium Therapeutics, Inc. (DFTX) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 5, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 38 figures on this page — 1 from SEC filings and earnings calls, 28 from Financial Modeling Prep (FMP), 7 with no recorded source, 1 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com